{"schema_version":"secwatch.filing_event.v1","accession":"0001161697-21-000375","form_type":"8-K","ticker":"KRMD","cik":"0000704440","company_name":"KORU Medical Systems, Inc.","filed_at":"2021-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.508212+00:00","generated_at":"2026-06-29T15:48:25.296748+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"KORU Medical Q2 net revenue $5.5M; net loss $1.1M; sequential growth of 2%","bullets":["Net revenue of $5.5 million, down 28.3% YoY but up 2% sequentially.","Gross margin 58.1%, down 5.6 ppts YoY due to lower volumes.","Net loss of $1.1 million ($0.03 diluted loss per share).","Non-GAAP adjusted EBITDA of $(0.3) million vs $1.8 million in Q2 2020.","Mid-single-digit growth in domestic immunoglobulin market and specialty pharmacy channel indicates market recovery."],"urls":{"canonical":"https://secwatch.observer/filing/0001161697-21-000375","json":"https://secwatch.observer/filing/0001161697-21-000375.json","markdown":"https://secwatch.observer/filing/0001161697-21-000375.md","text":"https://secwatch.observer/filing/0001161697-21-000375.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/704440/000116169721000375/0001161697-21-000375-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/704440/000116169721000375/form_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T15:48:25.296748+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}